RxDoctor Payments Data

Joshua Morrison, MD

Pulmonary Disease · Jonesboro, ARNPI 1083848956

Payments from drug & device makers

$2,600in general payments, 2019–2025

Across 164 payments — averaging $15.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$787
  • AstraZeneca$354
  • Jazz Pharmaceuticals Inc.$188
  • Regeneron Healthcare Solutions, Inc.$167
  • Boehringer Ingelheim$130
  • Sanofi$126
  • plus $847 from 21 others

What the payments were for

  • Food & beverage$2,56799%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,600 in reported general payments places this provider in the 40th percentile of 102 pulmonary disease providers in Arkansas.

See all pulmonary disease providers in Arkansas

Medicare billing

Part B allowed, 2024
$150,471
Medicare patients
644
Services billed
1,698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GlassiaAlpha-1-Proteinase Inhibitor12$193,868
Trelegy ElliptaFluticasone/Umeclidin/Vilanter94$62,234
Breztri AerosphereBudesonide/Glycopyr/Formoterol64$41,218
Breo ElliptaFluticasone/Vilanterol28$11,811
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$9,558
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$5,529
SymbicortBudesonide/Formoterol Fumarate20$5,359
Theophylline ErTheophylline Anhydrous45$4,397
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$4,361
Albuterol Sulfate HfaAlbuterol Sulfate102$3,321
BreynaBudesonide/Formoterol Fumarate17$3,095
Ventolin HfaAlbuterol Sulfate29$1,868
Levalbuterol Tartrate HfaLevalbuterol Tartrate20$1,115
Montelukast Sodium94$468
Prednisone62$267

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Glassia$71$193,86812 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$787$83,603143 claims
AstraZenecaBreztri Aerosphere, Symbicort$354$46,57784 claims
Boehringer IngelheimStiolto Respimat$130$5,52912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 102 pulmonary disease providers in Arkansas.

Other pulmonary disease in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →